ライフサイエンスコーパス: time since diagnosis

1 dex < 30, poor performance status, and short time since diagnosis).

2 )F-AV-1451 volume of distribution and age or time since diagnosis.

3 symptoms, or lacking health insurance at any time since diagnosis.

4 r, but this varies widely by cancer type and time since diagnosis.

5 Data were analyzed by type of cancer and time since diagnosis.

6 reasing age at diagnosis, and increased with time since diagnosis.

7 one groups after adjusting for age, sex, and time since diagnosis.

8 fter analysis was adjusted for age, sex, and time since diagnosis.

9 RC survivors were matched on sex, age, and time since diagnosis.

10 and that this association may be related to time since diagnosis.

11 imal associations between PTSS and length of time since diagnosis.

12 ation with treatment intensity and length of time since diagnosis.

13 e seen in both males and females with longer time since diagnosis.

14 sky performance status score, histology, and time since diagnosis.

15 and all-cause mortality varied with age and time since diagnosis.

16 atified by sex, age, cancer type, stage, and time since diagnosis.

17 (mean [SD] age, 14.2 [2.9] years, mean [SD] time since diagnosis, 10.9 [2.9] years; 153 [50.7%] male

18 enrolled in the Carolina Lupus Study (median time since diagnosis 13 months) was determined approxima

19 ; mean [SD] age, 31.7 [8.6] years; mean [SD] time since diagnosis, 21.2 [9.8] years) and 43 community

20 of HL (mean +/- SD age, 37.5 +/- 6.0 years; time since diagnosis, 23.6 +/- 4.7 years; 52.1% female)

21 teosarcoma (mean [SD] age, 38.9 [7.6] years; time since diagnosis, 24.7 [6.6] years; 42% female) were

22 ean [SD] age, 33.9 [9.1] years; median [IQR] time since diagnosis, 25.1 [18.7-31.9] years) with Europ

23 ; mean [SD] age, 39.6 [9.9] years; mean [SD] time since diagnosis, 31.7 [8.4] years).

24 ients with early atrial fibrillation (median time since diagnosis, 36 days) underwent randomization.

25 2,531 childhood-onset case subjects (median time since diagnosis 5 years).

26 women cancer survivors (age, 62 +/- 6 years; time since diagnosis, 5.8 +/- 4.1 years) categorized and

27 3 [IQR 57-72] years; 60 [63%] female; median time since diagnosis, 7 [IQR 6-9] years), 42 were analyz

28 Their decline was associated with time since diagnosis, activation levels, and the concomi

29 In simple models adjusted for time since diagnosis, age, and energy intake, animal fat

30 The recovery time since diagnosis and age influences recovery from HR

31 ce of risky health behaviors of survivors by time since diagnosis and cancer site.

32 Time since diagnosis and good performance status were si

33 Certain coping strategies were linked to time since diagnosis and location of vision loss.

34 The effect of time since diagnosis and quantitative anti-spike protein

35 regression to model the relationship between time since diagnosis and several sexual behavior variabl

36 hils, and monocytes increased gradually over time since diagnosis and were negatively correlated with

37 ences were <7% for all ages, both sexes, and times since diagnosis and for breast cancer, differences

38 egative predictors of PFS (high cfDNA, short time since diagnosis, and body mass index < 30) and 5 of

39 ancer screening) of cancer survivors by age, time since diagnosis, and cancer site.

40 ulmonary function category, distressed mood, time since diagnosis, and comorbidity) accounted for 37%

41 Children with cancer (n = 255) stratified by time since diagnosis, and demographically matched peers

42 size of 4), stratified by age at diagnosis, time since diagnosis, and history of chest-directed radi

43 ions exclusive to each biopsy increased with time since diagnosis, and late relapses shared few mutat

44 less than 70% of predicted, distressed mood, time since diagnosis, and more comorbid diseases (R(2) =

45 egardless of age, sex, race, stage IA vs IB, time since diagnosis, and number of prior therapies.

46 ociated with advancing disease stage, longer time since diagnosis, and poorer global cognition.

47 Gleason score, age, time since diagnosis, and prior treatments were document

48 sidering different RR, NS, age at diagnosis, time since diagnosis, and sex.

49 S survivors in relation to age at diagnosis, time since diagnosis, and treatments received.

50 Trends in opioid use over time since diagnosis are unknown.

51 an [range] age at diagnosis, 7 [0-21] years, time since diagnosis at baseline, 16 [6-30] years) and 7

52 urve analyses compared change in scores over time since diagnosis between groups.

53 lcohol consumption, and physical activity by time since diagnosis, but differences by cancer site exi

54 ciated with younger age at diagnosis, longer time since diagnosis, cranial radiation treatment, leuke

55 For any given time since diagnosis, crude annual breast cancer mortali

56 Age and time since diagnosis did not affect the magnitude of T-c

57 the DIRECT approach: D stands for delay, or time since diagnosis; I for pattern of immune deficiency

58 ss index [<=30 vs >30], stage II vs III, and time since diagnosis [<18 vs >=18 months]) to receive 30

59 a computer-generated sequence, stratified by time since diagnosis, lymph node involvement at diagnosi

60 After controlling for age, time since diagnosis, marital status, education, tumor s

61 lation with long-term disease who had a mean time since diagnosis of 10.6 years and 67% (88/131) of w

62 mean age of 45.2 years (SD 10.8), and a mean time since diagnosis of 7.3 years (5.8).

63 uate the effects on lung function of asthma, time since diagnosis of asthma, and age at diagnosis of

64 This association differed significantly by time since diagnosis of diabetes (p < 0.0002); risk of p

65 tionship between corneal sensitivity and the time since diagnosis of diabetes for a thermally cooling

66 xtended RAS status (wild-type vs mutant) and time since diagnosis of first metastasis (<18 months vs

67 Median time since diagnosis of Fontan circulation was 16 years

68 Time since diagnosis of HIV infection was shorter for th

69 n both groups were similar in regard to age, time since diagnosis of HIV infection, and CD4 cell coun

70 ive rates decreased somewhat with increasing time since diagnosis of LCIS, but were fairly stable aft

71 performance status of 0 or 1, with a median time since diagnosis of metastatic disease of 10 months

72 descriptive data, hemoglobin A1c (%) level, time since diagnosis of T1DM (months), and strain ratio

73 and the true value of NS, larger for longer time since diagnosis, older patients, and higher NS.

74 ption distortion; but not by pain intensity, time since diagnosis, or affected body side (left or rig

75 diagnosis, sex, cancer therapy, recurrence, time since diagnosis, or second malignancy.

76 lternative measure that accounts for elapsed time since diagnosis, providing more relevant prognostic

77 costs among cancer survivors, stratified by time since diagnosis (recently diagnosed [</= 1 year] an

78 All models were adjusted for age, time since diagnosis, stage, histology, and education le

79 een performance on the UPSIT and thymectomy, time since diagnosis, type of treatment regimen, or the

80 ts with DCIS, we examined trends in QoL over time since diagnosis using generalized linear regression

81 The mean (SD) time since diagnosis was 1.7 (1.0) years.

82 Forty-five patients were treated; median time since diagnosis was 14.1 months, and 51% of the pat

83 r the cranial radiation therapy group, while time since diagnosis was 15.0 (1.7) and 23.9 (3.1) years

84 Mean age was 33 years; mean time since diagnosis was 26 years.

85 In part 2 (32 patients), median time since diagnosis was 3.2 years, with a median of 2 p

86 nrolled, median age was 66 years, and median time since diagnosis was 5.3 years.

87 In part 2, the median time since diagnosis was 5.7 years.

88 Mean age was 70 years, 52% were male, mean time since diagnosis was 6 years, 69% had solid tumor ma

89 went solid organ transplantation, the median time since diagnosis was 6.3 years and the median 5yCSS

90 Longer time since diagnosis was associated with higher cumulati

91 9 SLE patients who had been employed at some time since diagnosis was drawn from a multicenter study

92 urity, WHO functional class, trisomy 21, and time since diagnosis were associated with height for age

93 Disease type, initial severity, and time since diagnosis were generally not associated with

94 also examined whether age, comorbidity, and time since diagnosis were related to PHC use.

95 ses and 99 controls matched by age, sex, and time since diagnosis were studied.

96 The association varied according to time since diagnosis with an adjusted IRR for 1 to 3 mon